Perspective Therapeutics (CATX) Cash & Equivalents (2010 - 2026)
Perspective Therapeutics (CATX) posted Cash & Equivalents of $270.9 million for Q1 2026, up 784.46% sequentially from $30.6 million in Q4 2025, and up 27.96% YoY from $211.7 million in Q1 2025.
Perspective Therapeutics (CATX) Cash & Equivalents (2010 - 2026) Analysis & Trends
Perspective Therapeutics has reported Cash & Equivalents for 17 years, with the latest figure at $270.9 million in Q1 2026.
- Quarterly Cash & Equivalents rose 27.96% year-over-year to $270.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $270.9 million (up 27.96% YoY) and the FY2025 annual result came in at $30.6 million, down 50.26% from the prior year.
- Cash & Equivalents advanced to $270.9 million in Q1 2026 per CATX's latest filing, from $30.6 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $270.9 million in Q1 2026 and troughed at $9.2 million in Q4 2023.
- A 5-year average of $100.1 million and a median of $55.9 million in 2022 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2024 and 2025: Cash & Equivalents surged 1389.18% in 2024, then plunged 90.01% in 2025.
- Over 5 years, Cash & Equivalents stood at $21.0 million in 2022, then plunged by 55.99% to $9.2 million in 2023, then surged by 566.59% to $61.6 million in 2024, then plunged by 50.26% to $30.6 million in 2025, then soared by 784.46% to $270.9 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $270.9 million, $30.6 million, and $26.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 5.10 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 3.39 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 1.95 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 539.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 2.91 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 1.11 Bn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 2.11 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 3.25 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 482.30 Mn |
| 10 | Perspective Therapeutics | 389.10 Mn | 389.10 Mn | - | 236.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 236.90 Mn |
| Mar 31, 2026 | 270.90 Mn |
| Dec 31, 2025 | 30.63 Mn |
| Sep 30, 2025 | 26.76 Mn |
| Jun 30, 2025 | 191.60 Mn |
| Mar 31, 2025 | 211.70 Mn |
| Dec 31, 2024 | 61.58 Mn |
| Sep 30, 2024 | 267.80 Mn |
| Jun 30, 2024 | 252.00 Mn |
| Mar 31, 2024 | 142.12 Mn |
| Dec 31, 2023 | 9.24 Mn |
| Sep 30, 2023 | 17.98 Mn |
| Jun 30, 2023 | 28.32 Mn |
| Mar 31, 2023 | 36.45 Mn |
| Dec 31, 2022 | 20.99 Mn |
| Sep 30, 2022 | 18.99 Mn |
| Jun 30, 2022 | 55.89 Mn |
| Mar 31, 2022 | 58.90 Mn |
| Dec 31, 2021 | 60.35 Mn |
| Sep 30, 2021 | 61.69 Mn |